Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Real-time Quote. Real-time Tradegate - 08/30 09:22:50 am
95.49 EUR   +0.42%
08/19 MERCK : EMD Serono Receives CEO Cancer Gold Standard ReAccreditation
08/16 MERCK : Millipore teams with TEAM Jaffrey
08/04DJMERCK KGAA : Lifts Profit Outlook as Sales Jump -- Update
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/24/2012 | 05:51pm CEST

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 
   Of  
 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; neetha.mahadevan@dowjones.com

(Sten Stovall contributed to this article.)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
08/25 MERCK : EMD Serono Receives CEO Cancer Gold Standard Re-Accreditation
08/19 MERCK : EMD Serono Receives CEO Cancer Gold Standard ReAccreditation
08/18 MERCK : Presolicitation Notice - Notice of Intent to Sole Source - EMD Millipore..
08/16 MERCK : Millipore teams with TEAM Jaffrey
08/15 DGAP-PVR : Merck KGaA: Release according to Article 26, Section 1 of the WpHG w..
08/15 DGAP-PVR : Merck KGaA: Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der ..
08/14 MERCK : SAFC y Stars participaron en el 2016 Team Up Day of Service
08/07 MERCK : Check out some of the numbers behind Greg Cochrane's career
08/04DJMERCK KGAA : Lifts Profit Outlook as Sales Jump -- Update
08/04DJMERCK KGAA : Lifts Profit Outlook as Sales Jump
More news
Sector news : Specialty & Advanced Pharmaceuticals
08:49aDJBusiness Watch -- WSJ
08/29 Mylan to launch generic EpiPen at half the price of original
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/29DJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
08/29DJROCHE : Receives US FDA Emergency Use Authorization for Zika Test
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
08/19 ALPHA FROM EQUAL-WEIGHTING : A Look At Materials
08/10 Bristol's Opdivo Fall-Out Brings Others Into Play
08/05 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q2 2016 Results - Earnings Call T..
08/04 Merck KGaA reports Q2 results
07/18 Merck's marketing application for Cladribine tablets accepted for review in E..
Advertisement
Financials (€)
Sales 2016 15 085 M
EBIT 2016 3 275 M
Net income 2016 1 620 M
Debt 2016 10 926 M
Yield 2016 1,29%
P/E ratio 2016 23,76
P/E ratio 2017 21,89
EV / Sales 2016 1,54x
EV / Sales 2017 1,37x
Capitalization 12 290 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 104 €
Spread / Average Target 9,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Laszlo Radvanyi Senior Vice President & Head-Research
Crocifissa Attardo Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA8.23%13 727
ABBVIE INC8.90%105 057
BIOGEN INC-0.07%67 079
KYOWA HAKKO KIRIN CO L..-24.99%8 048
MALLINCKRODT PLC-0.58%7 992
JAZZ PHARMACEUTICALS P..-9.84%7 671
More Results